We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Sertraline for the Prevention of Recurrent Postpartum Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00276900
Recruitment Status : Completed
First Posted : January 13, 2006
Last Update Posted : October 7, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study will determine the effectiveness of taking sertraline within 24 hours of giving birth in preventing a recurrence of postpartum depression.

Condition or disease Intervention/treatment Phase
Depression Drug: Sertraline Phase 3

Detailed Description:

Depression after pregnancy is called postpartum depression and may be caused by a rapid change in hormone levels during and immediately after pregnancy. Researchers believe that it is one of the most common complications linked to pregnancy. This type of depression occurs in 10 to 15% of women within the first 3 months of giving birth and it can negatively affect both mothers and their children. Mothers with postpartum depression may experience low energy, difficulty concentrating, irritability, and inability to meet their children's needs for love and affection. Research shows that children of mothers with postpartum depression may have delays in language development, difficulty with emotional bonding to others, behavioral problems, lower activity levels, sleep problems, and distress. Many women who have suffered from postpartum depression in the past are worried about a repeat episode with the birth of their next baby. This study will determine the effectiveness of taking sertraline within 24 hours of giving birth in preventing a recurrence of postpartum depression.

Participants in this double blind study will initially report to the study site two separate times while they are pregnant. At the first visit, which will last approximately 3 hours, medical and psychiatric histories will be taken. Blood and urine samples will also be collected at this time. At the second visit, which will last approximately 1 hour, participants will be randomly assigned to receive either sertraline or placebo for the year following childbirth. All participants will then either attend 10 clinic visits, each lasting 1 hour, or receive 17 phone calls over the course of the first 28 weeks postpartum. Mood symptoms and day-to-day functioning will be assessed. If the participant's baby is being breastfed, a blood sample will also be taken from the baby at Week 4 postpartum. At Week 12 postpartum, the baby will wear an actigraph to measure his or her activity for one week. At Week 24 postpartum, participants who are not depressed will be randomly assigned to either continue on sertraline or taper to placebo over 4 weeks. Those who were originally assigned to receive placebo will continue taking placebo for the remainder of the study. Starting at Week 29 postpartum, there will be approximately one clinic visit per month for the remainder of the year. Participants' functioning, ability to interact with their children, and symptoms of depression will be assessed at these visits.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Prevention of Recurrent Postpartum Depression
Study Start Date : December 2003
Primary Completion Date : August 2006
Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Depressive symptoms (measured at Weeks 24 and 52 postpartum)

Secondary Outcome Measures :
  1. Functioning (measured at Weeks 24 and 52 postpartum)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnant
  • Presents by week 36 gestation for first two study visit interviews (interviews may be combined)
  • History of DSM-IV Major Depression after the age of 15
  • Score no higher than 19 on the 29-item SIGH-ADS at Week 36
  • Medically healthy, as determined by a physician

Exclusion criteria

  • Current major depression
  • Urine screen positive for drugs
  • Currently using other therapies for depression
  • DSM-IV diagnoses of bipolar 1 or 2 disorder or any psychotic episode
  • History of substance abuse within 6 months prior to study entry
  • Has not received any obstetrical care
  • Use of medications for medical disorders (except for treatment of stable disorders)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276900

United States, Pennsylvania
Women's Behavioral HealthCare Program
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
National Institute of Mental Health (NIMH)
Principal Investigator: Katherine L. Wisner, MD Department of Psychiatry, University of Pittsburgh Medical Center
More Information

Additional Information:
Responsible Party: Katherine Wisner, Professor of Psychiatry, Obstetrics and Gynecology and Reproductive Sciences, Epidemiology and Women's Studies, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00276900     History of Changes
Other Study ID Numbers: R01MH053735 ( U.S. NIH Grant/Contract )
First Posted: January 13, 2006    Key Record Dates
Last Update Posted: October 7, 2013
Last Verified: September 2013

Keywords provided by Katherine Wisner, University of Pittsburgh:
Postpartum Depression
Recurrent Depression

Additional relevant MeSH terms:
Depressive Disorder
Depression, Postpartum
Behavioral Symptoms
Mood Disorders
Mental Disorders
Puerperal Disorders
Pregnancy Complications
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs